Cadrenal Therapeutics (NASDAQ: CVKD) is advancing novel therapies for life-threatening immune and thrombotic conditions, reflecting the broader principle that everyone deserves the opportunity to benefit from medical innovation and quality health care.
Its lead candidate, **CAD-1005**, a first-in-class 12-LOX inhibitor, recently presented late-breaking Phase 2 data at the ISTH 2026 Congress, reporting a **greater than 25% reduction in thrombotic events** in patients with heparin-induced thrombocytopenia (HIT), a serious and potentially life-threatening condition.
Continued research into treatments for underserved medical needs can help improve patient outcomes and support the goal of more equitable access to life-saving care.